Table 1 Patient characteristics, POC and subgroups of patients

Sex ratio (M:F)

59 (51.3%):56 (48.7%)

Age (years)

68 (39–89)

BMI (kg/m²)

27 (17–43)

Physical status classification ASA

 1/2/3/4

1 (0.9%)/33 (28.7%)/59 (51.3%)/22 (19.1%)

Comorbidities (overall)

53 (46.1%)

 Coronary artery disease

24 (20.9%)

 Diabetes mellitus

30 (26.1%)

 Thromboembolic disease

27 (23.5%)

Rectal resections

47 (40.9%)

 TaTME

16 (13.9%)

 Laparoscopic/open TME

14 (12.2%)/6 (5.2%)

 Laparoscopic PME

11 (9.6%)

 Operating time (min)

200 (90–380)

 Adenocarcinoma

38 (33.0%)

Adenoma with HG dysplasia

4 (3.5%)

 pCR after neoadjuvant CRT

3 (2.6%)

 No residual malignancy after LE

2 (1.7%)

 Upper/middle/distal rectum

26 (55.3%)/11 (23.4%)/11 (23.4%)

 Neoadjuvant therapy

29 (61.7%)

Colonic resections

68 (59.1%)

 Laparoscopic/open left colectomy

14 (12.2%)/6 (5.2%)

 Laparoscopic/open right colectomy

23 (20.0%)/23 (20.0%)

 Transverse colon resection

2 (1.7%)

 Operating time (min)

195 (75–380)

 Adenocarcinoma

55 (47.8%)

 Adenoma with HG dysplasia

10 (8.7%)

 NET

1 (0.9%)

 Lymphoma

2 (1.7%)

No complications/overall complications

66 (57.4%)/49 (42.6%)

Mortality

1 (0.9%)

Clavien‒Dindo

 1/2

1 (0.9%)/34 (29.6%)

 3a/3b

2 (1.7%)/3 (2.6%)

 4a/4b

6 (5.2%)/2 (1.7%)

 5

1 (0.9%)

Reoperation

10 (8.7%)

Anastomotic leak

6 (5.2%)

Paralytic ileus

15 (13%)

Urinary tract complications

8 (7%)

Wound complications

7 (6.1%)

Sepsis

4 (3.5%)

Medical complications

16 (13.9%)

Subgroups of patients

 CD > 3a

12 (10.4%)

 CD > 2

14 (12.2%)

 ICU (days)

4 (1; 60)

 ICU > 5 days

33 (28.7%)

 Hospital stay (days)

8 (6; 72)

 Hospital stay > 10 days

30 (26.1%)

 Antibiotic treatment

24 (20.9%)

 Inflammatory complication

29 (25.2%)